SCHEMBL12410263

SCHEMBL12410263

CCN1CCCC1CN(C/C(C)=C/c1ccccc1)C(=O)c1cc(OC)c(OC)c(OC)c1

nearest known ligand 0.72

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ACKR3 P25106 19/20 0.72
ABCG2 Q9UNQ0 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3540796 1.00 ACKR3 (0.72) ACKR3ABCG2
SCHEMBL3540794 1.00 ACKR3 (0.72) ACKR3ABCG2
SCHEMBL3540792 1.00 ACKR3 (0.72) ACKR3ABCG2
SCHEMBL3545859 0.92 ACKR3 (0.84) ACKR3
SCHEMBL3545857 0.92 ACKR3 (0.84) ACKR3
SCHEMBL3539871 0.91 ACKR3 (0.70) ACKR3
SCHEMBL3539874 0.91 ACKR3 (0.70) ACKR3
SCHEMBL12410267 0.91 ACKR3 (0.70) ACKR3
SCHEMBL3539870 0.91 ACKR3 (0.70) ACKR3
SCHEMBL12410264 0.90 ACKR3 (0.84) ACKR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110165164-A1 COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DISEASES AND CONDITIONS RELATED TO CHEMOKINE RECEPTORS CHEMOCENTRYX, INC. (US) 2011-07-07 US disclosed
US-20110165164-A1 COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DISEASES AND CONDITIONS RELATED TO CHEMOKINE RECEPTORS CHEMOCENTRYX, INC. (US) 2011-07-07 US disclosed
US-7871619-B2 Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors CHEMOCENTRYX, INC. (US) 2011-01-18 US disclosed
US-7871619-B2 Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors CHEMOCENTRYX, INC. (US) 2011-01-18 US disclosed
US-20100144720-A1 INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-06-10 US disclosed
US-20100144720-A1 INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-06-10 US disclosed
US-7649011-B2 Active against cancer proliferation, growth, and metastasis; such as 3,4,5-trimethoxy-n-(2-methyl-3-phenyl-allyl)-n-[2-(1-methyl-pyrrolidin-2-yl)-thyl]-benzamide; side effect reduction CHEMOCENTRYX, INC. (US) 2010-01-19 US disclosed
US-7649011-B2 Active against cancer proliferation, growth, and metastasis; such as 3,4,5-trimethoxy-n-(2-methyl-3-phenyl-allyl)-n-[2-(1-methyl-pyrrolidin-2-yl)-thyl]-benzamide; side effect reduction CHEMOCENTRYX, INC. (US) 2010-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110165164-A1 COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DISEASES AND CONDITIONS RELATED TO CHEMOKINE RECEPTORS CXCR3, CXCR2, ACKR3 ACKR3 3/4885ABCG2 2778/4885
US-20100144720-A1 INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2 CCL2, CCR2, CXCR2 ACKR3 12/4885ABCG2 627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.